Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies

• Published in: Cancer Immunology, Immunotherapy Vol. 36; no. 2; pp. 65 - 75
• Main Authors: HORAN HAND, P, ROBBINS, P. F, SALGALLER, M. L, POOLE, D. J, SCHLOM, J
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.03.1993; Springer-Verlag
• Subjects: Animals; Antibodies - blood; Antibodies, Monoclonal - metabolism; Antibodies, Monoclonal - therapeutic use; Antineoplastic agents; Biological and medical sciences; Carcinoembryonic Antigen - analysis; Carcinoembryonic Antigen - genetics; Carcinoembryonic Antigen - immunology; Immunotherapy; Medical sciences; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental - immunology; Neoplasms, Experimental - therapy; Original; Pharmacology. Drug treatments; Transduction, Genetic; Tumor Cells, Cultured; Adenocarcinoma; Fibrosarcoma; Monoclonal antibody; Carcinoembryonic antigen; Transfection; Immunotherapy; Colon; Tumor cell; Human; Tumor associated antigen; Rodentia; Tumorigenicity; Malignant tumor; In vitro; In vivo; Vertebrata; Experimental disease; Mammalia; Cell line; Treatment; Complementary DNA; Mouse; Animal; Digestive diseases; Comparative study
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/BF01754404

The MC-38 C57BL/6 mouse colon adenocarcinoma cell line has been transduced with a retroviral construct containing cDNA encoding the human carcinoembryonic antigen (CEA) gene [Robbins PF, Kantor JA, Salgaller M, Horan Hand P, Fernsten PD, Schlom J (1991) Cancer Res 51: 3657]. Two clones, MC-38-ceal and MC-38-cea2, expressed high levels of CEA on their cell surface. A third CEA-expressing cell line, MCA-102-cea3, was similarly derived by transduction of the MCA-102 C57BL/6 mouse fibrosarcoma cell line and is described here. In this study, the three CEA-transduced murine tumor cell lines (MC-38-ceal, MC-38-cea2, MCA-102-cea3) were evaluated for their tumorigenic potential, as well as their ability to serve as in vivo model systems for active and passive immunotherapy studies. Parameters that were investigated include tumor growth rate, the antibody response of the host to CEA, and the CEA content of the tumors. The MC-38-cea2 model appeared to be the most appropriate for immunotherapy studies. Biodistribution studies, using an 125I-labeled anti-CEA mAb, demonstrated efficient tumor targeting of MC-38-cea2 tumors in C57BL/6 and athymic mice.